Vildapin
Generic Name
Vildagliptin
Manufacturer
Renata Limited
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| vildapin 50 mg tablet | ৳ 15.04 | ৳ 150.40 |
Description
Overview of the medicine
Vildapin 50 mg tablet contains Vildagliptin, an oral antidiabetic drug used for the treatment of type 2 diabetes mellitus. It helps to control blood sugar levels by increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner.
Uses & Indications
Dosage
Adults
The recommended dose is 50 mg or 100 mg daily. For monotherapy or in combination with metformin, a thiazolidinedione, or insulin, the recommended daily dose is 50 mg or 100 mg, given as 50 mg once daily or 50 mg twice daily. For combination with a sulfonylurea, the recommended daily dose is 50 mg once daily.
Elderly
No dose adjustment is required in elderly patients.
Renal_impairment
For patients with moderate to severe renal impairment (creatinine clearance <50 mL/min), the recommended dose is 50 mg once daily.
How to Take
Vildapin tablets should be taken orally, with or without food. If a dose is split into two, one tablet should be taken in the morning and one in the evening.
Mechanism of Action
Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by inhibiting the breakdown of incretin hormones (GLP-1 and GIP), which are released from the gut in response to food. This leads to increased levels of active incretin hormones, enhancing glucose-dependent insulin secretion from pancreatic beta cells and reducing glucagon secretion from pancreatic alpha cells, thereby lowering blood glucose levels.
Pharmacokinetics
Onset
Within hours of administration, with sustained effect on incretin levels.
Excretion
Approximately 85% of the dose is excreted in the urine, with 15% excreted in the feces. Renal excretion of unchanged drug is about 23%.
Half life
The terminal elimination half-life is approximately 2-3 hours.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1.7-2.5 hours. Oral bioavailability is 85%.
Metabolism
Primarily metabolized by hydrolysis (69% of dose) via the enzyme NVP277. CYP450 enzymes are minimally involved.
Side Effects
Contraindications
- Hypersensitivity to Vildagliptin or any excipients of the tablet.
- Patients with severe hepatic impairment.
- Patients with New York Heart Association (NYHA) functional class IV heart failure.
Drug Interactions
ACE Inhibitors
Increased risk of angioedema when co-administered with ACE inhibitors.
Thiazides, Corticosteroids, Thyroid products, Sympathomimetics
May reduce the hypoglycemic effect of Vildagliptin.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Limited information is available regarding overdose. In cases of overdose, general supportive measures should be initiated as dictated by the patient's clinical status. Vildagliptin can be removed by hemodialysis.
Pregnancy & Lactation
Vildagliptin should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. It is unknown whether Vildagliptin is excreted in human milk, so caution should be exercised when administered to a nursing woman.
Side Effects
Contraindications
- Hypersensitivity to Vildagliptin or any excipients of the tablet.
- Patients with severe hepatic impairment.
- Patients with New York Heart Association (NYHA) functional class IV heart failure.
Drug Interactions
ACE Inhibitors
Increased risk of angioedema when co-administered with ACE inhibitors.
Thiazides, Corticosteroids, Thyroid products, Sympathomimetics
May reduce the hypoglycemic effect of Vildagliptin.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Limited information is available regarding overdose. In cases of overdose, general supportive measures should be initiated as dictated by the patient's clinical status. Vildagliptin can be removed by hemodialysis.
Pregnancy & Lactation
Vildagliptin should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. It is unknown whether Vildagliptin is excreted in human milk, so caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture, refer to the product packaging for exact expiry date.
Availability
Available in pharmacies and hospitals nationwide
Approval Status
Approved by DGDA (Bangladesh)
Patent Status
Generically available in many countries; original patent expired or nearing expiration in some regions
Clinical Trials
Vildagliptin has undergone extensive clinical trials demonstrating its efficacy and safety in patients with type 2 diabetes mellitus, both as monotherapy and in combination with other antidiabetic agents.
Lab Monitoring
- Glycated hemoglobin (HbA1c) levels regularly to assess glycemic control.
- Renal function tests (e.g., serum creatinine, eGFR) periodically.
- Liver function tests (ALT, AST) before initiation and periodically during treatment.
Doctor Notes
- Emphasize patient education on lifestyle modifications (diet, exercise) as integral to diabetes management.
- Monitor renal function, especially in elderly patients or those with pre-existing kidney impairment.
- Advise patients to report any symptoms of pancreatitis (e.g., severe persistent abdominal pain) or liver problems (e.g., unexplained nausea, vomiting, dark urine) immediately.
Patient Guidelines
- Take Vildapin exactly as prescribed by your doctor.
- Do not stop taking this medicine without consulting your doctor, even if you feel well.
- This medicine is part of a complete treatment program that includes diet, exercise, and weight control.
Missed Dose Advice
If a dose is missed, it should be taken as soon as the patient remembers. However, if it is almost time for the next dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. Do not take a double dose to make up for a missed one.
Driving Precautions
Vildapin alone is unlikely to cause hypoglycemia and thus should not impair the ability to drive or use machines. However, if Vildapin is used in combination with a sulfonylurea or insulin, hypoglycemia may occur, which could affect driving ability. Patients should be advised on the risks of hypoglycemia.
Lifestyle Advice
- Follow a balanced diet as recommended by your healthcare provider.
- Engage in regular physical activity to help manage blood sugar levels.
- Maintain a healthy weight, as obesity can worsen type 2 diabetes.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.